Retinoids as differentiating agents in oncology: A network of interactions with intracellular pathways as the basis for rational therapeutic combinations

Current Pharmaceutical Design

Volumn 13, Issue 13, 2007, Pages 1375-1400

  Garattini, Enrico ^a   Gianni, Maurizio ^a   Terao, Mineko ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Acute myeloid leukemia; All trans retinoic acid; Hedgehog pathway; Neuroblastoma; RXR agonists

Indexed keywords

3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALITRETINOIN; ANTINEOPLASTIC AGENT; BEXAROTENE; COLECALCIFEROL; CYCLIC AMP DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; DELTA 1 NOTCH RECEPTOR; FENRETINIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; ISOTRETINOIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PICLAMILAST; PROTEIN KINASE C INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA AGONIST; RETINOIC ACID RECEPTOR ALPHA ANTAGONIST; RETINOIC ACID RECEPTOR GAMMA AGONIST; RETINOID; ST 1346; STI 1926; STRESS ACTIVATED PROTEIN KINASE; TAMIBAROTENE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN ANTAGONIST;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; CUTANEOUS T CELL LYMPHOMA; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SYNTHESIS; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MELANOMA; MONOTHERAPY; MYELOID LEUKEMIA; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TERATOCARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; HUMANS; INTRACELLULAR FLUID; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOIDS; SIGNAL TRANSDUCTION;

EID: 34248575347     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618786     Document Type: Review

References (346)

1. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-5.
2. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, et al. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993; 85: 499-500.
3. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
4. Sankowski A, Janik P, Jeziorska M, Swietochowska B, Ciesla W, Malek A, et al. The results of topical application of 13-cis-retinoic acid on basal cell carcinoma. A correlation of the clinical effect with histopathological examination and serum retinol level. Neoplasma 1987; 34: 485-9.
5. Gravis G, Pech-Gourgh F, Viens P, Alzieu C, Camerlo J, Oziel-Taieb S, et al. Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma. Anticancer Drugs 1999; 10: 369-74.
6. Studer UE, Biedermann C, Chollet D, Karrer P, Kraft R, Toggenburg H, et al. Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland. J Urol 1984; 131: 47-9.
7. Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28: 284-90.
8. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17: 1065-71.
9. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72: 567-72.
10. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-9.
11. Warrell RP, Jr Frankel SR, Miller WH, Jr Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93.
12. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-43.
13. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-67.
14. Leone G, Sica S, Ortu La Barbera E, Testa U, Riccioni R, Labbaye C, et al. Secondary leukemia responsive to retinoic acid with abnormal localization of RARalpha protein: a report of two cases. Blood 1998; 91: 4811-2.
15. Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML, et al. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood 2001; 98: 2862-4.
16. Garattini E, Terao M. Cytodifferentiation: a novel approach to cancer treatment and prevention. Curr Opin Pharmacol 2001; 1: 358-63.
17. Grande A, Montanari M, Manfredini R, Tagliafico E, Zanocco-Marani T, Trevisan F,et al. A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Cell Death Differ 2001; 8: 70-82.
18. Manfredini R, Trevisan F, Grande A, Tagliafico E, Montanari M, Lemoli R,et al. Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Res 1999; 59: 3803-11.
19. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-58.
20. Lazzarino M, Regazzi MB, Corso A. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Leuk Lymphoma 1996; 23: 539-43.
21. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-83.
22. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH, et al. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-8.
23. Chambon P. A decade of molecular biology of retinoic acid receptors. Faseb J 1996; 10: 940-54.
24. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 1995; 83: 859-69.
25. Lohnes D, Dierich A, Ghyselinck N, Kastner P, Lampron C, Le-Meur M, et al. Retinoid receptors and binding proteins. J Cell Sci Suppl 1992; 16: 69-76.
26. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995 83: 841-50.
27. Mangelsdorf DJ, Kliewer SA, Kakizuka A, Umesono K, Evans RM. Retinoid receptors. Recent Prog Horm Res 1993; 48: 99-121.
28. Wei LN. Retinoids and receptor interacting protein 140 (RIP140) in gene regulation. Curr Med Chem 2004; 11: 1527-32.
29. Weston AD, Blumberg B, Underhill TM. Active repression by unliganded retinoid receptors in development: less is sometimes more. J Cell Biol 2003; 161: 223-8.
30. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999; 9: 140-7.
31. Gronemeyer H, Miturski R. Molecular mechanisms of retinoid action. Cell Mol Biol Lett 2001; 6: 3-52.
32. Westin S, Rosenfeld MG, Glass CK. Nuclear receptor coactivators. Adv Pharmacol 2000; 47: 89-112.
33. Edwards DP. Coregulatory proteins in nuclear hormone receptor action. Vitam Horm 1999; 55: 165-218.
34. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 1997; 9: 222-32.
35. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997; 52: 141-64 discussion 164-45.
36. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 2003; 15: 355-66.
37. Gianni M, Parrella E, Raska I, Jr Gaillard E, Nigro EA, Gaudon C, et al. P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription. EMBO J 2006; 25: 739-51.
38. Parrella E, Gianni M, Cecconi V, Nigro E, Barzago MM, Rambaldi A, et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways. J Biol Chem 2004; 279: 42026-40.
39. Gianni M, Tarrade A, Nigro EA, Garattini E, Rochette-Egly C. The AF-1 and AF-2 domains of RAR gamma 2 and RXR alpha cooperate for triggering the transactivation and the degradation of RAR gamma 2/RXR alpha heterodimers. J Biol Chem 2003; 278: 34458-66.
40. Gianni M, Kopf E, Bastien J, Oulad-Abdelghani M, Garattini E, Chambon P, et al. Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2. J Biol Chem 2002; 277: 24859-62.
41. Gianni M, Bauer A, Garattini E, Chambon P, Rochette-Egly C. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J 2002; 21: 3760-9.
42. Beehler BC, Brinckerhoff CE, Ostrowski J. Selective retinoic acid receptor ligands for rheumatoid arthritis. Curr Opin Investig Drugs 2004; 5: 1153-7.
43. Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem 1997 40: 3567-83.
44. Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr Pharm Des 2003 9: 2067-77.
45. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997; 37: S12-7.
46. Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol 1998; 39: S124-8.
47. Chandraratna RA. Future trends: a new generation of retinoids. J Am Acad Dermatol 1998; 39: S149-52.
48. Crowe DL. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr Cancer Drug Targets 2002; 2: 77-86.
49. Strickland S, Breitman TR, Frickel F, Nurrenbach A, Hadicke E, Sporn MB. Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res 1983; 43: 5268-72.
50. Pignatello MA, Kauffman FC, Levin AA. Multiple factors contribute to the toxicity of the aromatic retinoid TTNPB (Ro 13-7410): interactions with the retinoic acid receptors. Toxicol Appl Pharmacol 1999; 159: 109-16.
51. Tamura K, Kagechika H, Hashimoto Y, Shudo K, Ohsugi K, Ide H. Synthetic retinoids, retinobenzoic acids, Am80, Am580 and Ch55 regulate morphogenesis in chick limb bud. Cell Differ Dev 1990; 32: 17-26.
52. Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, et al. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. Blood 1996; 87: 1520-31.
53. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003; 17: 1454-63.
54. Germain P, Kammerer S, Perez E, Peluso-Iltis C, Tortolani D, Zusi FC, et al. Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep 2004; 5: 877-82.
55. Garattini E, Gianni M, Terao M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr Pharm Des 2004; 10: 433-48.
56. Ponzanelli I, Gianni M, Giavazzi R, Garofalo A, Nicoletti I, Reichert U, et al. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 2000; 95: 2672-82.
57. Mologni L, Ponzanelli I, Bresciani F, Sardiello G, Bergamaschi D, Gianni M, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999; 93: 1045-61.
58. Alvarez R, Vega MJ, Kammerer S, Rossin A, Germain P, Gronemeyer H, et al. 9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett 2004; 14: 6117-22.
59. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 2004; 16: 421-8.
60. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, et al. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5774-8.
61. Li XY, Xiao JH, Feng X, Qin L, Voorhees JJ. Retinoid X receptor-specific ligands synergistically upregulate 1, 25-dihydroxyvitamin D3-dependent transcription in epidermal keratinocytes in vitro and in vivo. J Invest Dermatol 1997; 108: 506-12.
62. Kang S, Li XY, Duell EA, Voorhees JJ. The retinoid X receptor agonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. J Invest Dermatol 1997; 108: 513-8.
63. Li Y, Hashimoto Y, Agadir A, Kagechika H, Zhang X. Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J Biol Chem 1999; 274: 15360-6.
64. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996; 38: 85-96.
65. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995; 15: 3540-51.
66. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995; 38: 3146-55.
67. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J 1995; 14: 1187-97.
68. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994; 372: 107-11.
69. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995; 270: 923-27.
70. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
71. Gianni M, Ponzanelli I, Mologni L, Reichert U, Rambaldi A, Terao M, et al. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ 2000; 7: 447-60.
72. Lomo J, Smeland EB, Ulven S, Natarajan V, Blomhoff R, Gandhi U, et al. RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes. J Cell Physiol 1998; 175: 68-77.
73. Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol 2003; 16: 387-408.
74. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-215.
75. Guidez F, Huang W, Tong JH, Dubois C, Balitrand N, Waxman S, et al. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 1994; 8: 312-7.
76. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 1994; 91: 1178-82.
77. Gaines P, Berliner N. Retinoids in myelopoiesis. J Biol Regul Homeost Agents 2003; 17: 46-65.
78. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002; 16: 1896-05.
79. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-6.
80. Bastie JN, Balitrand N, Guillemot I, Chomienne C, Delva L. Cooperative action of 1alpha,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. Exp Cell Res 2005; 310: 319-30.
81. Cao Y, Wang F, Liu HY, Fu ZD, Han R. Resveratrol induces apoptosis and differentiation in acute promyelocytic leukemia (NB4) cells. J Asian Nat Prod Res 2005; 7: 633-41.
82. Idres N, Benoit G, Flexor MA, Lanotte M, Chabot GG. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res 2001; 61: 700-5.
83. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, Garattini E. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. Blood 2001; 97: 3234-43.
84. Gianni M, Li Calzi M, Terao M, Rambaldi A, Garattini E. Tyrosine kinases but not cAMP-dependent protein kinase mediate the induction of leukocyte alkaline phosphatase by granulocyte-colonystimulating factor and retinoic acid in acute promyelocytic leukemia cells. Biochem Biophys Res Commun 1995; 208: 846-54.
85. Gianni M, Norio P, Terao M, Falanga A, Marchetti M, Rambaldi A, et al. Effects of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells. Eur Cytokine Netw 1995; 6: 157-65.
86. Gianni M, Terao M, Norio P, Barbui T, Rambaldi A, Garattini E. All-trans retinoic acid and cyclic adenosine monophosphate cooperate in the expression of leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. Blood 1995; 85: 3619-35.
87. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, Barbui T, et al. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997; 89: 1001-12.
88. Gianni M, Terao M, Zanotta S, Barbui T, Rambaldi A, Garattini E. Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. Blood 1994; 83: 1909-21.
89. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000; 16: 1084-9.
90. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003; 197: 185-92.
91. Carpentier A, Balitrand N, Rochette-Egly C, Shroot B, Degos L, Chomienne C. Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers. Oncogene 1997; 15: 1805-13.
92. Joshi S, Guleria R, Pan J, DiPette D, Singh US. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SHSY5Y cells. Oncogene 2006; 25: 240-7.
93. Lovat PE, Irving H, Annicchiarico-Petruzzelli M, Bernassola F, Malcolm AJ, Pearson AD, et al. Retinoids in neuroblastoma therapy: distinct biological properties of 9-cis- and all-trans-retinoic acid. Eur J Cancer 1997; 33: 2075-80.
94. Melino G, Draoui M, Bellincampi L, Bernassola F, Bernardini S, Piacentini M, et al. Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells. Exp Cell Res 1997; 235: 55-61.
95. Nguyen T, Hocker JE, Thomas W, Smith SA, Norris MD, Haber M, et al. Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Commun 2003; 302: 462-8.
96. Cheung B, Hocker JE, Smith SA, Norris MD, Haber M, Marshall GM. Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. Oncogene 1998; 17: 751-9.
97. Chu PW, Cheung WM, Kwong YL. Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 2003; 14: 1935-9.
98. Castel V, Canete A. A comparison of current neuroblastoma chemotherapeutics. Expert Opin Pharmacother 2004; 5: 71-80.
99. Veal GJ, Errington J, Redfern CP, Pearson AD, Boddy AV. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochem Pharmacol 2002; 63: 207-15.
100. Lotan R. Roles of retinoids and their nuclear receptors in the development and prevention of upper aerodigestive tract cancers. Environ Health Perspect 1997; 105 Suppl 4: 985-8.
101. Higuchi E, Chandraratna RA, Hong WK, Lotan R. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 2003; 22: 4627-35.
102. Satake K, Takagi E, Ishii A, Kato Y, Imagawa Y, Kimura Y, et al. Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. Auris Nasus Larynx 2003; 30: 403-12.
103. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000 6: 1702-10.
104. Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, Batsakis JG, et al. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3: 875-80.
105. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, et al. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 2004; 10: 1733-42.
106. Klaassen I, Brakenhoff RH, Smeets SJ, Snow GB, Braakhuis BJ. Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. Int J Cancer 2001; 92: 661-5.
107. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res 1996; 16: 2415-9.
108. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000 6: 1563-73.
109. Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, et al. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res 1999; 5: 431-7.
110. Xu XC, Liu X, Tahara E, Lippman SM, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res 1999; 59: 2477-83.
111. Paik J, Blaner WS, Sommer KM, Moe R, Swisshlem K. Retinoids, retinoic acid receptors, and breast cancer. Cancer Invest 2003; 21: 304-12.
112. Yang Q, Sakurai T, Kakudo K. Retinoid, retinoic acid receptor beta and breast cancer. Breast Cancer Res Treat 2002; 76: 167-73.
113. del Rincon SV, Rousseau C, Samanta R, Miller WH, Jr.: Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway. Oncogene 2003; 22: 3353-60.
114. Seewaldt VL, Kim JH, Parker MB, Dietze EC, Srinivasan KV, Caldwell LE. Dysregulated expression of cyclin D1 in normal human mammary epithelial cells inhibits all-trans-retinoic acid-mediated G0/G1-phase arrest and differentiation in vitro. Exp Cell Res 1999; 249: 70-85.
115. Di Lorenzo D, Gianni M, Savoldi GF, Ferrari F, Albertini A, Garattini E. Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells. Biochem Biophys Res Commun 1993; 192: 1066-72.
116. Jing Y, Zhang J, Waxman S, Mira-y-Lopez R. Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 1996; 60: 109-17.
117. Petersen OW, Ronnov-Jessen L, Weaver VM, Bissell MJ. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy. Adv Cancer Res 1998; 75: 135-61.
118. Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 1995; 6: 863-9.
119. Yang Q, Sakurai T, Yoshimura G, Mori I, Nakamura M, Nakamura Y, et al. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma. Anticancer Res 2001; 21: 1829-33.
120. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997; 57: 4158-61.
121. Schneider SM, Offterdinger M, Huber H, Grunt TW. Activation of retinoic acid receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells. Cancer Res 2000; 60: 5479-87.
122. Rousseau C, Nichol JN, Pettersson F, Couture MC, Miller WH, Jr.: ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk. Mol Cancer Res 2004; 2: 523-31.
123. Laganiere J, Deblois G, Giguere V. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol 2005; 19: 1584-92.
124. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005; 4: 477-86.
125. Alonso A, Breuer B, Steuer B, Fischer J. The F9-EC cell line as a model for the analysis of differentiation. Int J Dev Biol 1991; 35: 389-97.
126. Grabel L, Becker S, Lock L, Maye P, Zanders T. Using EC and ES cell culture to study early development: recent observations on Indian hedgehog and Bmps. Int J Dev Biol 1998; 42: 917-25.
127. Lehtonen E, Laasonen A, Tienari J. Teratocarcinoma stem cells as a model for differentiation in the mouse embryo. Int J Dev Biol 1989; 33: 105-15.
128. Bain G, Ray WJ, Yao M, Gottlieb DI. From embryonal carcinoma cells to neurons: the P19 pathway. Bioessays 1994; 16: 343-8.
129. Ingraham CA, Cox ME, Ward DC, Fults DW, Maness PF. c-src and other proto-oncogenes implicated in neuronal differentiation. Mol Chem Neuropathol 1989; 10: 1-14.
130. Shen Y, Mani S, Meiri KF. Failure to express GAP-43 leads to disruption of a multipotent precursor and inhibits astrocyte differentiation. Mol Cell Neurosci 2004; 26: 390-405.
131. Gajovic S, St-Onge L, Yokota Y, Gruss P. Retinoic acid mediates Pax6 expression during in vitro differentiation of embryonic stem cells. Differentiation 1997; 62: 187-92.
132. Renoncourt Y, Carroll P, Filippi P, Arce V, Alonso S. Neurons derived in vitro from ES cells express homeoproteins characteristic of motoneurons and interneurons. Mech Dev 1998; 79: 185-97.
133. Gianni M, Studer M, Carpani G, Terao M, Garattini E. Retinoic acid induces liver/bone/kidney-type alkaline phosphatase gene expression in F9 teratocarcinoma cells. Biochem J 1991; 274(Pt 3): 673-8.
134. Gianni M, Zanotta S, Terao M, Garattini S, Garattini E. Effects of synthetic retinoids and retinoic acid isomers on the expression of alkaline phosphatase in F9 teratocarcinoma cells. Biochem Biophys Res Commun 1993; 196: 252-9.
135. Rochette-Egly C, Chambon P. F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. Histol Histopathol 2001; 16: 909-22.
136. Taneja R, Rochette-Egly C, Plassat JL, Penna L, Gaub MP, Chambon P. Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J 1997; 16: 6452-65.
137. Faria TN, Mendelsohn C, Chambon P, Gudas LJ. The targeted disruption of both alleles of RARbeta(2) in F9 cells results in the loss of retinoic acid-associated growth arrest. J Biol Chem 1999; 274: 26783-8.
138. Huang Y, Boskovic G, Niles RM. Retinoic acid-induced AP-1 transcriptional activity regulates B16 mouse melanoma growth inhibition and differentiation. J Cell Physiol 2003; 194: 162-70.
139. Desai SH, Niles RM. Characterization of retinoic acid-induced AP-1 activity in B16 mouse melanoma cells. J Biol Chem 1997; 272: 12809-15.
140. O'Connor TJ, Fujita DJ. Differentiation of B16 murine melanoma cells is associated with an increased level of c-SRC. Melanoma Res 1995; 5: 5-13.
141. Niles RM. Vitamin A (retinoids) regulation of mouse melanoma growth and differentiation. J Nutr 2003; 133: 282S-6S.
142. Emionite L, Galmozzi F, Raffo P, Vergani L, Toma S. Retinoids and malignant melanoma: a pathway of proliferation inhibition on SK MEL28 cell line. Anticancer Res 2003; 23: 13-9.
143. Demary K, Wong L, Liou JS, Faller DV, Spanjaard RA. Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells. Endocrinology 2001; 142: 2600-5.
144. Higuchi T, Kizaki M, Omine M. Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. Leuk Res 2004; 28: 525-32.
145. Imaizumi M, Sato A, Koizumi Y, Inoue S, Suzuki H, Suwabe N, et al. Potentiated maturation with a high proliferating activity of acute promyelocytic leukemia induced in vitro by granulocyte or granulocyte/macrophage colony-stimulating factors in combination with all-trans retinoic acid. Leukemia 1994; 8: 1301-8.
146. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992; 80: 2012-20.
147. Tkatch LS, Rubin KA, Ziegler SF, Tweardy DJ. Modulation of human G-CSF receptor mRNA and protein in normal and leukemic myeloid cells by G-CSF and retinoic acid. J Leukoc Biol 1995; 57: 964-71.
148. Shimodaira S, Kitano K, Nishizawa Y, Ichikawa N, Ishida F, Kamino I, et al. Acute myelogenous leukemia with a t(2;17;4) (p13;q21;p16) aberration: effective treatment with all-trans retinoic acid and granulocyte colony-stimulating factor. Intern Med 1999; 38: 150-4.
149. Roberts AB, Sporn MB. Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-beta. Cancer Surv 1992; 14: 205-20.
150. Sporn MB, Roberts AB. Suppression of carcinogenesis by retinoids: interactions with peptide growth factors and their receptors as a key mechanism. Princess Takamatsu Symp 1985; 16: 149-58.
151. Sporn MB, Roberts AB, Wakefield LM, Glick AB, Danielpour D. Transforming growth factor-beta and suppression of carcinogenesis. Princess Takamatsu Symp 1989; 20: 259-66.
152. Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M. Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. J Cell Sci Suppl 1990; 13: 139-48.
153. Cao Z, Flanders KC, Bertolette D, Lyakh LA, Wurthner JU, Parks WT, et al. Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 2003; 101: 498-507.
154. Gomez-Santos C, Ambrosio S, Ventura F, Ferrer I, Reiriz J. TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res 2002; 958: 152-60.
155. Turley JM, Falk LA, Ruscetti FW, Kasper JJ, Francomano T, Fu T, et al. Transforming growth factor beta 1 functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Differ 1996; 7: 1535-44.
156. Walz TM, Malm C, Wasteson A. Expression of the transforming growth factor alpha protooncogene in differentiating human promyelocytic leukemia (HL-60) cells. Cancer Res 1993; 53: 191-6.
157. De Benedetti F, Falk LA, Ellingsworth LR, Ruscetti FW, Faltynek CR. Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines. Blood 1990; 75: 626-32.
158. Valette A, Botanch C. Transforming growth factor beta (TGF-beta) potentiates the inhibitory effect of retinoic acid on human breast
159. Lauritsen KJ, List HJ, Reiter R, Wellstein A, Riegel AT. A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 2002; 21: 7147-55.
160. Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs. J Cell Biochem 1994; 56: 427-35.
161. Chelbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia 1999; 13: 1167-74.
162. Eisenhauer EA, Lippman SM, Kavanagh JJ, Parades-Espinoza M, Arnold A, Hong WK, et al. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 1994; 8: 1622-5.
163. Fossa SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101: 533-40.
164. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-64.
165. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, et al. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19: 3010-17.
166. Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc Natl Acad Sci USA 1999; 96: 13956-61.
167. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 2002; 23: 96-101.
168. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene 2000; 19: 2619-27.
169. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
170. Garattini E, Mologni L, Ponzanelli I, Terao M. Cross-talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells. Leuk Lymphoma 1998; 30: 467-75.
171. Gianni M, Zanotta S, Terao M, Rambaldi A, Garattini E. Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers. Int J Cancer 1996, 68: 75-83.
172. Lembo D, Gaboli M, Caliendo A, Falciani F, Garattini E, Landolfo S. Regulation of the 202 gene expression by interferons in L929 cells. Biochem Biophys Res Commun 1992; 187: 628-34.
173. Dimberg A, Karlberg I, Nilsson K, Oberg F. Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood 2003; 102: 254-61.
174. Dimberg A, Nilsson K, Oberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood 2000; 96: 2870-8.
175. Matikainen S, Lehtonen A, Sareneva T, Julkunen I. Regulation of IRF and STAT gene expression by retinoic acid. Leuk Lymphoma 1998; 30: 63-71.
176. Matikainen S, Ronni T, Hurme M, Pine R, Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996; 88: 114-23.
177. Matikainen S, Ronni T, Lehtonen A, Sareneva T, Melen K, Nordling S, et al. Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ 1997; 8: 687-98.
178. Pelicano L, Li F, Schindler C, Chelbi-Alix MK. Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene 1997; 15: 2349-59.
179. Percario ZA, Giandomenico V, Fiorucci G, Chiantore MV, Vannucchi S, Hiscott J, et al. Retinoic acid is able to induce interferon regulatory factor 1 in squamous carcinoma cells via a STAT-1 independent signalling pathway. Cell Growth Differ 1999; 10: 263-70.
180. Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003; 278: 32544-51.
181. Kolla V, Lindner DJ, Xiao W, Borden EC, Kalvakolanu DV. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 1996; 271: 10508-14.
182. Kolla V, Weihua X, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J Biol Chem 1997; 272: 9742-8.
183. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 1997; 3: 931-7.
184. Moore DM, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994; 31: 31-7.
185. Altucci L, Gronemeyer H. Decryption of the retinoid death code in leukemia. J Clin Immunol 2002; 22: 117-23.
186. Altucci L, Gronemeyer H. Retinoids and TRAIL: two cooperating actors to fight against cancer. Vitam Horm 2004; 67: 319-45.
187. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-6.
188. Jimenez-Lara AM, Clarke N, Altucci L, Gronemeyer H. Retinoicacid-induced apoptosis in leukemia cells. Trends Mol Med 2004; 10: 508-15.
189. Egyed M, Kollar B, Rumi G, Keller E, Vass J, Fekete S. Effect of retinoic acid treatment on cytogenetic remission of chronic myeloid leukaemia. Acta Haematol 2003; 109: 84-9.
190. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-50.
191. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
192. Appel B, Eisen JS. Retinoids run rampant: multiple roles during spinal cord and motor neuron development. Neuron 2003; 40: 461-4.
193. Lupo G, Harris WA, Lewis KE. Mechanisms of ventral patterning in the vertebrate nervous system. Nat Rev Neurosci 2006; 7: 103-14.
194. Murata-Ohsawa M, Tohda S, Kogoshi H, Sakano S, Nara N. The Notch ligand, Delta-1, alters retinoic acid (RA)-induced neutrophilic differentiation into monocytic and reduces RA-induced apoptosis in NB4 cells. Leuk Res 2005; 29: 197-203.
195. Ye Q, Shieh JH, Morrone G, Moore MA. Expression of constitutively active Notch4 (Int-3) modulates myeloid proliferation and differentiation and promotes expansion of hematopoietic progenitors. Leukemia 2004; 18: 777-87.
196. Shibamoto S, Winer J, Williams M, Polakis P. A blockade in Wnt signaling is activated following the differentiation of F9 teratocarcinoma cells. Exp Cell Res 2004; 292: 11-20.
197. Liu T, Lee YN, Malbon CC, Wang HY. Activation of the betacatenin/Lef-Tcf pathway is obligate for formation of primitive endoderm by mouse F9 totipotent teratocarcinoma cells in response to retinoic acid. J Biol Chem 2002; 277: 30887-91.
198. Katoh M. Regulation of WNT signaling molecules by retinoic acid during neuronal differentiation in NT2 cells: threshold model of WNT action (review). Int J Mol Med 2002; 10: 683-7.
199. Wakeman JA, Walsh J, Andrews PW. Human Wnt-13 is developmentally regulated during the differentiation of NTERA-2 pluripotent human embryonal carcinoma cells. Oncogene 1998; 17: 179-86.
200. Freemantle SJ, Kerley JS, Olsen SL, Gross RH, Spinella MJ. Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma. Oncogene 2002; 21: 2880-9.
201. Lyu J, Costantini F, Jho EH, Joo CK. Ectopic expression of Axin blocks neuronal differentiation of embryonic carcinoma P19 cells. J Biol Chem 2003; 278: 13487-95.
202. Fisher GJ, Talwar HS, Lin J, Lin P, McPhillips F, Wang Z, et al. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 1998; 101: 1432-40.
203. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997; 11: 3351-64.
204. Gonzalez MV, Gonzalez-Sancho JM, Caelles C, Munoz A, Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett 1999; 459: 272-6.
205. Easwaran V, Pishvaian M, Salimuddin, Byers S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999; 9: 1415-8.
206. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26: 898-915.
207. Tice DA, Szeto W, Soloviev I, Rubinfeld B, Fong SE, Dugger DL, et al. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J Biol Chem 2002; 277: 14329-35.
208. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999; 59: 1869-76.
209. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000; 19: 1002-09.
210. Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, et al. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 2003; 278: 29954-62.
211. Jette C, Peterson PW, Sandoval IT, Manos EJ, Hadley E, Ireland CM, et al. The tumor suppressor adenomatous polyposis coli and caudal related homeodomain protein regulate expression of retinol dehydrogenase L. J Biol Chem 2004; 279: 34397-05.
212. Mollersen L, Paulsen JE, Olstorn HB, Knutsen HK, Alexander J. Dietary retinoic acid supplementation stimulates intestinal tumour formation and growth in multiple intestinal neoplasia (Min)/+ mice. Carcinogenesis 2004; 25: 149-53.
213. Mangioni S, Vigano P, Lattuada D, Abbiati A, Vignali M, Di Blasio AM. Overexpression of the Wnt5b gene in leiomyoma cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor. J Clin Endocrinol Metab 2005; 90: 5349-55.
214. Blanc E, Goldschneider D, Douc-Rasy S, Benard J, Raguenez G. Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett 2005; 228: 117-23.
215. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-04.
216. Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood 2004; 103: 3535-43.
217. Imaizumi M, Breitman TR. Retinoic acid-induced differentiation of the human promyelocytic leukemia cell line, HL-60, and fresh human leukemia cells in primary culture: a model for differentiation inducing therapy of leukemia. Eur J Haematol 1987; 38: 289-02.
218. Breitman TR, Chen ZX, Takahashi N. Potential applications of cytodifferentiation therapy in hematologic malignancies. Semin Hematol 1994; 31: 18-25.
219. Yang KD, Chao CY, Shaio MF. Pentoxifylline synergizes with all-trans retinoic acid to induce differentiation of HL-60 myelocytic cells, but suppresses tRA-augmented clonal growth of normal CFU-GM. Acta Haematol 1998; 99: 191-9.
220. Garattini E, Gianni M. Leukocyte alkaline phosphatase a specific marker for the post-mitotic neutrophilic granulocyte: regulation in acute promyelocytic leukemia. Leuk Lymphoma 1996; 23: 493-03.
221. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 2005; 65: 8754-65.
222. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 2002; 196: 1373-80.
223. Kamashev D, Vitoux D, De The H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 2004; 199: 1163-74.
224. Taimi M, Breitman TR, Takahashi N. Cyclic AMP-dependent protein kinase isoenzymes in human myeloid leukemia (HL60) and breast tumor (MCF-7) cells. Arch Biochem Biophys 2001; 392: 137-44.
225. Abemayor E, Sidell N. Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 1989; 80: 3-15.
226. Holtzer H, Biehl J, Holtzer S. Induction-dependent and lineage-dependent models for cell diversification are mutually exclusive. Prog Clin Biol Res 1985; 175: 3-11.
227. Rochette-Egly C, Oulad-Abdelghani M, Staub A, Pfister V, Scheuer I, Chambon P, et al. Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. Mol Endocrinol 1995; 9: 860-71.
228. Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W, et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. Embo J 1999; 18: 7011-8.
229. Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemother Pharmacol 2001; 47: 126-32.
230. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
231. Shimada K, Nakamura M, Ishida E, Konishi N. Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 2006; 21: 415-22.
232. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55: 1230-54.
233. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005; 115: 2633-9.
234. Ouyang DY, Wang YY, Zheng YT. Activation of c-Jun N-terminal kinases by ribotoxic stresses. Cell Mol Immunol 2005; 2: 419-25.
235. Shen HM, Liu ZG. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006; 40: 928-39.
236. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996; 79: 162-73.
237. Mehta KD, Miller L. Inhibition of stress-activated p38 mitogenactivated protein kinase induces low-density lipoprotein receptor expression. Trends Cardiovasc Med 1999; 9: 201-5.
238. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68: 320-44.
239. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002; 16: 683-92.
240. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 2001; 80: 471-82.
241. Yen A, Roberson MS, Varvayanis S. Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38 MAP kinases when inducing myeloid differentiation. In Vitro Cell Dev Biol Anim 1999; 35: 527-32.
242. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-72.
243. Verheijen MH, Wolthuis RM, Bos JL, Defize LH. The Ras/Erk pathway induces primitive endoderm but prevents parietal endoderm differentiation of F9 embryonal carcinoma cells. J Biol Chem 1999; 274: 1487-94.
244. Nakagawa S, Fujii T, Yokoyama G, Kazanietz MG, Yamana H, Shirouzu K. Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Calpha and extracellular signal-regulated kinase mitogen-activated protein kinase. Mol Carcinog 2003; 38: 106-16.
245. Miloso M, Villa D, Crimi M, Galbiati S, Donzelli E, Nicolini G, et al. Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent. J Neurosci Res 2004; 75: 241-52.
246. Ishaq M, Fan M, Natarajan V. Accumulation of RXR alpha during activation of cycling human T lymphocytes: modulation of RXRE transactivation function by mitogen-activated protein kinase pathways. J Immunol 2000; 165: 4217-25.
247. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-68.
248. Karin M, Shaulian E. AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death. IUBMB Life 2001; 52: 17-24.
249. Allenby G. The ying-yang of RAR and AP-1: cancer treatment without overt toxicity. Hum Exp Toxicol 1995; 14: 226-30.
250. Pisano C, Kollar P, Gianni M, Kalac Y, Giordano V, Ferrara FF, et al. Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. Blood 2002; 100: 3719-30.
251. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93: 329-39.
252. Wang Q, Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 2004; 23: 426-33.
253. Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol 1999; 19: 1973-80.
254. Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC, et al. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol 2005; 25: 1054-69.
255. Adam-Stitah S, Penna L, Chambon P, Rochette-Egly C. Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases. J Biol Chem 1999; 274: 18932-41.
256. Bruck N, Bastien J, Bour G, Tarrade A, Plassat JL, Bauer A, et al. Phosphorylation of the retinoid x receptor at the omega loop, modulates the expression of retinoic-acid-target genes with a promoter context specificity. Cell Signal 2005; 17: 1229-39.
257. Mann KK, Padovani AM, Guo Q, Colosimo AL, Lee HY, Kurie JM, et al. Jr. Arsenic trioxide inhibits nuclear receptor function via SEK1/ JNK-mediated RXRalpha phosphorylation. J Clin Invest 2005; 115: 2924-33.
258. Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu DV, Minucci S, et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001; 276: 4012-9.
259. Wang XZ, Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 1996; 272: 1347-9.
260. Verbeek W, Gombart AF, Chumakov AM, Muller C, Friedman AD, Koeffler HP. C/EBPepsilon directly interacts with the DNA binding domain of c-myb and cooperatively activates transcription of myeloid promoters. Blood 1999; 93: 3327-37.
261. Tenen DG. Abnormalities of the CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 2001; 15: 688-9.
262. Gery S, Park DJ, Vuong PT, Chih DY, Lemp N, Koeffler HP. Retinoic acid regulates C/EBP homologous protein expression (CHOP), which negatively regulates myeloid target genes. Blood 2004; 104: 3911-7.
263. Teruel T, Hernandez R, Benito M, Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J Biol Chem 2003; 278: 263-9.
264. Dai X, Yamasaki K, Shirakata Y, Sayama K, Hashimoto K. All-trans-retinoic acid induces interleukin-8 via the nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways in normal human keratinocytes. J Invest Dermatol 2004; 123: 1078-85.
265. Palm-Leis A, Singh US, Herbelin BS, Olsovsky GD, Baker KM, Pan J. Mitogen-activated protein kinases and mitogen-activated protein kinase phosphatases mediate the inhibitory effects of all-trans retinoic acid on the hypertrophic growth of cardiomyocytes. J Biol Chem 2004; 279: 54905-17.
266. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 2004; 1697: 89-01.
267. DiCamillo AM, Neff NT, Carswell S, Haun FA. Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP-1347/KT-7515 in rats with lesions of nucleus basalis magnocellularis. Neuroscience 1998; 86: 473-83.
268. Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 2005; 26: 455-61.
269. Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation. Arthritis Rheum 2005; 52: 2719-29.
270. Bogoyevitch MA. Therapeutic promise of JNK ATP-noncompetitive inhibitors. Trends Mol Med 2005; 11: 232-9.
271. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101: 703-5.
272. Koskela K, Pelliniemi TT, Pulkki K, Remes K. Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial. Leuk Lymphoma 2004; 45: 749-54.
273. Musto P, Falcone A, Sajeva MR, D'Arena G, Bonini A, Carotenuto M. All-trans retinoic acid for advanced multiple myeloma. Blood 1995; 85: 3769-70.
274. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via downregulation of IL-6 receptors. J Immunol 1991; 146: 3809-14.
275. Lopez-Carballo G, Moreno L, Masia S, Perez P, Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 2002; 277: 25297-04.
276. Carter CA, Madden VJ. A newly characterized human endometrial adenocarcinoma cell line (CAC-1) differentiates in response to retinoic acid treatment. Exp Mol Pathol 2000; 69: 175-91.
277. Bastien J, Plassat JL, Payrastre B, Rochette-Egly C. The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene 2006; 25: 2040-7.
278. Lal L, Li Y, Smith J, Sassano A, Uddin S, Parmar S, et al. Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005; 105: 1669-77.
279. Ishida S, Shudo K, Takada S, Koike K. Transcription from the P2 promoter of human protooncogene myc is suppressed by retinoic acid through an interaction between the E2F element and its binding proteins. Cell Growth Differ 1994; 5: 287-94.
280. Neri LM, Borgatti P, Tazzari PL, Bortul R, Cappellini A, Tabellini G, et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003; 1: 234-46.
281. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 17: 1794-05.
282. Farias EF, Ong DE, Ghyselinck NB, Nakajo S, Kuppumbatti YS, Mira y Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J Natl Cancer Inst 2005; 97: 21-9.
283. Hisatake J, O'Kelly J, Uskokovic MR, Tomoyasu S, Koeffler HP. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 2001; 97: 2427-33.
284. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J 2006; 395: 653-62.
285. Siwak DR, Mendoza-Gamboa E, Tari AM. HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDAMB-453 breast cancer cells. Int J Oncol 2003; 23: 1739-45.
286. Tari AM, Lim SJ, Hung MC, Esteva FJ, Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002; 21: 5224-32.
287. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, et al. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 2001; 276: 27907-12.
288. Tawara I, Nishikawa M, Morita K, Kobayashi K, Toyoda H, Omay SB, et al. Down-regulation by retinoic acid of the catalytic subunit of protein phosphatase type 2A during granulocytic differentiation of HL-60 cells. FEBS Lett 1993; 321: 224-8.
289. Morita K, Nishikawa M, Kobayashi K, Deguchi K, Ito M, Nakano T, et al. Augmentation of retinoic acid-induced granulocytic differentiation in HL-60 leukemia cells by serine/threonine protein phosphatase inhibitors. FEBS Lett 1992; 314: 340-44.
290. Ramirez CJ, Haberbusch JM, Soprano DR, Soprano KJ. Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells. J Cell Biochem 2005; 96: 170-82.
291. Wang J, Barsky LW, Shum CH, Jong A, Weinberg KI, Collins SJ, et al. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem 2002; 277: 43369-76.
292. Rochette-Egly C, Adam S, Rossignol M, Egly JM, Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 1997; 90: 97-07.
293. Pareek TK, Kulkarni AB. Cdk5: a new player in pain signaling. Cell Cycle 2006; 5: 585-8.
294. Jung HY, Park SH, Yoo YD, Kim JS, Kim YH. CDK2/4 regulate retinoic acid-induced G1 arrest in hepatocellular carcinoma cells. Hepatol Res 2005; 31: 143-52.
295. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 1999; 248: 87-96.
296. Alisi A, Leoni S, Piacentani A, Conti Devirgiliis L. Retinoic acid modulates the cell-cycle in fetal rat hepatocytes and HepG2 cells by regulating cyclin-cdk activities. Liver Int 2003; 23: 179-86.
297. Hsu SL, Hsu JW, Liu MC, Chen LY, Chang CD. Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells. Exp Cell Res 2000; 258: 322-31.
298. Vuocolo S, Soprano DR, Soprano KJ. p27/Kip1 mediates retinoic acid-induced suppression of ovarian carcinoma cell growth. J Cell Physiol 2004; 199: 237-43.
299. Gompel M, Soulie C, Ceballos-Picot I, Meijer L. Expression and activity of cyclin-dependent kinases and glycogen synthase kinase- 3 during NT2 neuronal differentiation. Neurosignals 2004; 13: 134-43.
300. Gaetano C, Matsumoto K, Thiele CJ. Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation. Cell Growth Differ 1991; 2: 487-93.
301. Bour G, Gaillard E, Bruck N, Lalevee S, Plassat JL, Busso D, et al. Cyclin H binding to the RARalpha activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7. Proc Natl Acad Sci USA 2005; 102: 16608-13.
302. Bastien J, Adam-Stitah S, Riedl T, Egly JM, Chambon P, Rochette-Egly C. TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7. J Biol Chem 2000; 275: 21896-04.
303. Keriel A, Stary A, Sarasin A, Rochette-Egly C, Egly JM. XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha. Cell 2002; 109: 125-35.
304. He Q, Peng H, Collins SJ, Triche TJ, Wu L. Retinoid-modulated MAT1 ubiquitination and CAK activity. FASEB J 2004; 18: 1734-36.
305. Costa SL, Pratt MA, McBurney MW (Ed): E2F inhibits transcriptional activation by the retinoic acid receptor; 1996.
306. Lee JH, Kim KT. Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells. J Neurochem 2004; 91: 634-47.
307. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 1998; 4: 2885-90.
308. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9: 161-7.
309. Aggarwal S, Kim SW, Cheon K, Tabassam FH, Yoon JH, Koo JS. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol Biol Cell 2006; 17: 566-75.
310. Cho Y, Tighe AP, Talmage DA. Retinoic acid induced growth arrest of human breast carcinoma cells requires protein kinase C alpha expression and activity. J Cell Physiol 1997; 172: 306-13.
311. Khuri FR, Cho Y, Talmage DA. Retinoic acid-induced transition from protein kinase C beta to protein kinase C alpha in differentiated F9 cells: correlation with altered regulation of proto-oncogene expression by phorbol esters. Cell Growth Differ 1996; 7: 595-02.
312. Yang KD, Mizobuchi T, Kharbanda SM, Datta R, Huberman E, Kufe DW, et al. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood 1994; 83: 490-6.
313. Yung BY, Hui EK. Differential Cellular Distribution of Retinoic Acid during Staurosporine Potentiation of Retinoic Acid-Induced Granulocytic Differentiation in Human Leukemia HL-60 Cells. J Biomed Sci 1995; 2: 154-9.
314. Bertolaso L, Gibellini D, Secchiero P, Previati M, Falgione D, Visani G, et al. Accumulation of catalytically active PKC-zeta into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-trans retinoic acid. Br J Haematol 1998; 100: 541-9.
315. Tahayato A, Lefebvre P, Formstecher P, Dautrevaux M. A protein kinase C-dependent activity modulates retinoic acid-induced transcription. Mol Endocrinol 1993; 7: 1642-53.
316. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P. Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR.RARalpha heterodimerization and transcriptional activity. J Biol Chem 1999; 274: 38225-31.
317. Ishaq M, Fan M, Wigmore K, Gaddam A, Natarajan V. Regulation of retinoid X receptor responsive element-dependent transcription in T lymphocytes by Ser/Thr phosphatases: functional divergence of protein kinase C (PKC)theta; and PKC alpha in mediating calcineurin- induced transactivation. J Immunol 2002; 169: 732-8.
318. Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Pontremoli S, Melloni E. Human neuroblastoma cell differentiation requires protein kinase C-theta. Biochem Biophys Res Commun 2000; 279: 589-94.
319. Cho Y, Klein MG, Talmage DA. Distinct functions of protein kinase Calpha and protein kinase Cbeta during retinoic acidinduced differentiation of F9 cells. Cell Growth Differ 1998; 9: 147-54.
320. Pettersson F, Couture MC, Hanna N, Miller WH. Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK. Oncogene 2004; 23: 7053-66.
321. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000; 484: 217-23.
322. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 1998; 281: 2042-5.
323. Radominska-Pandya A, Chen G, Czernik PJ, Little JM, Samokyszyn VM, Carter CA, et al. Direct interaction of all-trans-retinoic acid with protein kinase C (PKC). Implications for PKC signaling and cancer therapy. J Biol Chem 2000; 275: 22324-30.
324. Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M, et al. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 2005; 24: 1820-30.
325. Jones LC, Tefferi A, Idos GE, Kumagai T, Hofmann WK, Koeffler HP. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 2004; 23: 7846-53.
326. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-82.
327. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene 2001; 20: 5726-35.
328. Salomoni P, Pandolfi PP. Transcriptional regulation of cellular transformation. Nat Med 2000; 6: 742-4.
329. Warrell RP, Jr He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-5.
330. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 48(Suppl 1): S17-19.
331. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP, Jr Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321-30.
332. Hanabata T, Tsukuda K, Toyooka S, Yano M, Aoe M, Nagahiro I, et al. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers. Oncol Rep 2004; 12: 177-80.
333. Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, et al. Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer 2002; 2: 4.
334. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000; 92: 826-32.
335. Ekmekci CG, Gutierrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 2004; 77: 233-40.
336. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003; 107: 970-5.
337. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003; 9: 1596-03.
338. Cote S, Momparler RL. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 1997; 8: 56-61.
339. Okuse K, Mizuno N, Matsuoka I, Kurihara K. Induction of cholinergic and adrenergic differentiation in N-18 cells by differentiation agents and DNA demethylating agents. Brain Res 1993; 626: 225-33.
340. Yu KH, Weng LJ, Fu S, Piantadosi S, Gore SD. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia 1999; 13: 1258-65.
341. Emionite L, Galmozzi F, Grattarola M, Boccardo F, Vergani L, Toma S. Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines. Anticancer Res 2004; 24: 4019-24.
342. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61: 1477-85.
343. Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, De Propris MS, et al. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 2002; 100: 1065-7.
344. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
345. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-9.
346. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220-5.